Titan Pharmaceuticals, Inc. (TTNP) financial statements (2020 and earlier)

Company profile

Business Address 400 OYSTER POINT BLVD
SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments59814815
Cash and cash equivalents59814815
Receivables120444
Inventory, net of allowances, customer advances and progress billings11    
Inventory11    
Other undisclosed current assets111000
Total current assets:8138181220
Noncurrent Assets
Operating lease, right-of-use asset0
Property, plant and equipment111111
Total noncurrent assets:111111
TOTAL ASSETS:10149191321
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities221445
Accounts payable121344
Accrued liabilities110100
Deferred revenue1
Debt013   
Deferred revenue and credits   2
Other undisclosed current liabilities010000
Total current liabilities:434557
Noncurrent Liabilities
Long-term debt and lease obligation444   
Long-term debt, excluding current maturities444   
Operating lease, liability0
Liabilities, other than long-term debt 0    
Derivative instruments and hedges, liabilities 0    
Other undisclosed noncurrent liabilities0  116
Total noncurrent liabilities:444116
Total liabilities:8785612
Stockholders' equity
Stockholders' equity attributable to parent, including:1711379
Common stock00298298298289
Additional paid in capital35033926242322
Accumulated deficit(349)(333)(323)(309)(314)(303)
Warrants and rights outstanding     6
Other undisclosed stockholders' equity attributable to parent     (6)
Total stockholders' equity:1711379
TOTAL LIABILITIES AND EQUITY:10149191321

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues4701524
Revenue, net01524
Cost of revenue
(Cost of Goods and Services Sold)
(1)(1)    
Gross profit:2601524
Operating expenses(19)(15)(15)(11)(8)(7)
Other undisclosed operating income 1    
Operating income (loss):(17)(8)(15)4(7)(3)
Nonoperating income (expense)0(1)01(5)1
Other nonoperating income (expense)0(0)(0)(0)(0)(0)
Interest and debt expense0 11  
Income (loss) from continuing operations before income taxes:(16)(9)(14)6(11)(2)
Income tax benefit     0
Net income (loss):(16)(9)(14)6(11)(2)
Other undisclosed net loss attributable to parent(0) (1)(1) (0)
Net income (loss) attributable to parent:(16)(9)(14)5(11)(2)
Other undisclosed net loss available to common stockholders, basic (0)    
Net income (loss) available to common stockholders, basic:(16)(9)(14)5(11)(2)
Other undisclosed net loss available to common stockholders, diluted (0)(1)(1) (1)
Net income (loss) available to common stockholders, diluted:(16)(9)(15)4(11)(3)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):(16)(9)(14)6(11)(2)
Comprehensive income (loss):(16)(9)(14)6(11)(2)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 1828(1)235
Comprehensive income (loss), net of tax, attributable to parent:(16)9145112

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: